MedPage Today on MSN
Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial
Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...
MedPage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...
Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results